AVO — Advanced Oncotherapy Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Annual income statement for Advanced Oncotherapy, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2017 December 31st | R2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 0 | -1.91 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Total Operating Expenses | 14.5 | 21.8 | 20.7 | 20.3 | 23.7 |
| Operating Profit | -14.5 | -21.8 | -20.7 | -20.3 | -23.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -16.5 | -21.9 | -21.9 | -25.3 | -29.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -13.7 | -21.2 | -20.8 | -25.3 | -29.5 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -13.7 | -21.1 | -20.8 | -25.3 | -29.5 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -13.7 | -21.1 | -20.8 | -25.3 | -29.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.176 | -0.14 | -0.098 | -0.088 | -0.077 |